Table 5 Studies which report asthma hospitalization/ED visit, maintenance medications use (steroid or salbutamol) etc
Study | Study type | Group | Sample (Trial/Control) | Duration of treatment | Results (statin group compared with the control group) |
|---|---|---|---|---|---|
Huang et al., [30] | Retrospective study | Statin exposed vs statin unexposed | 11808(3965/7843) | 4.66 ± 2.32 years | Hospitalization/ED visit (p=0.006) ↓ |
Ostroukhova et al., [18] | Retrospective study | Statin exposed vs statin unexposed | 50(24/26) | 2 years | Maintenance medication (p=0.005), nocturnal awakenings(P=0.001), office visits(P=0.003) and albuterol use (p=0.001) ↑ |
Christiansen et al., [17] | Retrospective study | Statin exposed vs statin unexposed | 43158(7783/35375) | Not mentioned | Risk ratios were 1.2 for Hospitalizations/ED visits and 1.17 for oral corticosteroid diepemsing ↑ |
Stanek et al., [13] | Retrospective study | Statin exposed vs statin unexposed | 6574(2103/4471) | 1 year | Hospitalization/ED visit (p < 0.001) ↓ |
Moskovljevic et al., [28] | Controlled clinical trial | Atorvastatin(10mg/day) vs placebo | 9 | 4 weeks | Morbidity ↓ |
Pagovich et al., [26] | Retrospective study | Atorvastatin, simvastatin vs baseline | 70 | 4 weeks | Albuterol use(p<0.0001) ↓ |
Fahimi et al., [23] | RCT | Atorvastatin(10mg/day) vs placebo | 17 | 4 weeks | Morbidity (p=0.42) ↓ |
Feschenko et al., [14] | RCT | Atorvastatin+ICS+Salbutamol vs ICS+salbutamol | 31 | 4 weeks | Night symptoms, cough, dialy symptoms and use of salbutamol (p<0.05) ↓ |
Lokhandwala et al., [31] | Retrospective study | Statin exposed vs statin unexposed | 1437(479/958) | 1 year | Hospitalization/ED visit (p=0.0059) ↓ |